Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Abstract

Background: Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed to support decision making. A countrywide mass vaccination campaign with the use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) was conducted in Chile starting on February 2, 2021.

Methods: We used a prospective national cohort, including participants 16 years of age or older who were affiliated with the public national health care system, to assess the effectiveness of the inactivated SARS-CoV-2 vaccine with regard to preventing Covid-19 and related hospitalization, admission to the intensive care unit (ICU), and death. We estimated hazard ratios using the extension of the Cox proportional-hazards model, accounting for time-varying vaccination status. We estimated the change in the hazard ratio associated with partial immunization (≥14 days after receipt of the first dose and before receipt of the second dose) and full immunization (≥14 days after receipt of the second dose). Vaccine effectiveness was estimated with adjustment for individual demographic and clinical characteristics.

Results: The study was conducted from February 2 through May 1, 2021, and the cohort included approximately 10.2 million persons. Among persons who were fully immunized, the adjusted vaccine effectiveness was 65.9% (95% confidence interval [CI], 65.2 to 66.6) for the prevention of Covid-19 and 87.5% (95% CI, 86.7 to 88.2) for the prevention of hospitalization, 90.3% (95% CI, 89.1 to 91.4) for the prevention of ICU admission, and 86.3% (95% CI, 84.5 to 87.9) for the prevention of Covid-19-related death.

Conclusions: Our results suggest that the inactivated SARS-CoV-2 vaccine effectively prevented Covid-19, including severe disease and death, a finding that is consistent with results of phase 2 trials of the vaccine. (Funded by Agencia Nacional de Investigación y Desarrollo and others.).

Copyright © 2021 Massachusetts Medical Society.

Figures

Figure 1. Study Participants and Cohort Eligibility.

Participants were at least 16 years of age, were affiliated with Fondo Nacional de Salud (FONASA; the national public health care system in Chile), and either had received at least one dose of the CoronaVac vaccine between February 2 and May 1, 2021, or had not received any vaccination. We excluded persons who had probable or confirmed coronavirus disease 2019 (Covid-19) according to reverse-transcriptase–polymerase-chain-reaction assay for severe acute respiratory syndrome coronavirus 2 and all persons who had been immunized with the BNT162b2 vaccine.

Figure 2. Vaccination Rollout and Crude Cumulative Incidence of Covid-19 in the Study Cohort.

Panel A shows the pace and coverage of the vaccination program among persons who received both doses of vaccine (first and second doses shown separately) or only one dose during the study period (February 2 through May 1, 2021). Panel B shows the crude cumulative incidence of Covid-19 during the study period among unvaccinated persons, among persons who had received only one dose of vaccine, and among persons who had received both doses of vaccine. The relatively high cumulative incidence of Covid-19 in the one-dose group should be interpreted with caution. As shown in Panel A, this group initiated vaccination approximately 40 days after the beginning of the vaccination campaign on February 2, 2021. Therefore, the incidence curve includes all cases that occurred from before vaccination up to 13 days after receipt of the first dose. Shading on the lines indicates 95% confidence intervals.